Trial Investigates Combined Empagliflozin and Liraglutide for Heart Failure in Diabetes

Patients with Type 2 Diabetes Mellitus often face an increased risk of developing congestive heart failure (CHF), a serious condition where the heart cannot pump enough blood effectively. Existing treatments like SGLT2 inhibitors (e.g., empagliflozin) and GLP-1 receptor agonists (e.g., liraglutide) have shown individual benefits for both diabetes and cardiovascular outcomes. However, there's a significant knowledge gap regarding the specific mechanistic insights and potential synergistic effects of combining these two drug classes in managing CHF in diabetic patients.